{"id":71409,"date":"2026-05-20T09:18:16","date_gmt":"2026-05-20T09:18:16","guid":{"rendered":"https:\/\/medsbase.com\/l-carnitine\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"l-carnitine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/de\/product\/l-carnitine\/","title":{"rendered":"L-Carnitin (Levocarnitin)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Kurze Antwort \u2014 Was ist L-Carnitin?<\/h3>\n<p style=\"margin: 0;\"><strong>L-Carnitin<\/strong> (Levocarnitin; (3R)-3-Hydroxy-4-(trimethylammonio)butanoat) ist ein kleines quart\u00e4res Ammonium-Aminos\u00e4urederivat \u2014 <em>kein Peptid<\/em> \u2014 that functions as the essential carrier molecule for transporting long-chain fatty acids across the mitochondrial inner membrane for \u03b2-oxidation. It is endogenously biosynthesised from L-lysine and L-methionine and is concentrated in skeletal muscle, heart, and liver. L-Carnitine is studied across mitochondrial-function studies, fat-oxidation physiology, insulin-sensitivity models, cardiovascular studies, neuroprotection (Alzheimer \/ autism in-vitro work), exercise physiology, and sperm-motility studies. Supplied in 600 mg and 1200 mg vials as levocarnitine USP-grade zwitterion for clinical studies use only. Stocked in our peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD\u207a<\/a> as a complementary mitochondrial \/ metabolic support-injectable.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Was Sie bei MedsBase erhalten:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/de\/reviews\/\">Kundenbewertungen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jede Bestellung ist durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> abgedeckt \u2014 wenn Ihr Paket nicht innerhalb von 20 Werktagen ankommt, versenden wir es erneut.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Spezifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">541-15-1 (L-Carnitin-Innensalz\/Zwitterion)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Typ<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Quaternary-Ammonium-Aminos\u00e4ure-Derivat (<em>kein Peptid<\/em>); das linksdrehende (3R)-Enantiomer ist die biologisch aktive Form, die f\u00fcr den mitochondrialen Transport langkettiger Fetts\u00e4uren \u00fcber das Carnitin-Palmitoyltransferase (CPT-I \/ CPT-II)-System verantwortlich ist; endogen aus L-Lysin und L-Methionin biosynthetisiert; auch als Levocarnitin (INN) oder Vitamin B<sub>T<\/sub> in \u00e4lterer Literatur<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekularformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>7<\/sub>H<sub>15<\/sub>NEIN<sub>3<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">161.20 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>IUPAC-Name<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">(3R)-3-Hydroxy-4-(trimethylazaniumyl)butanoat<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (kleines Molek\u00fcl-Aminos\u00e4ure-Derivat \u2013 kein Peptid)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat, wei\u00df bis wei\u00dflich (Zwitterion \/ Innensalz-Form)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Reinheit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-best\u00e4tigt, COA auf Anfrage)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Lagerung<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisiert: 2\u20138 \u00b0C (K\u00fchlschrank) f\u00fcr kurzfristige Arbeitsvorr\u00e4te; \u221220 \u00b0C f\u00fcr die Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituiert: 2\u20138 \u00b0C, innerhalb von ~30 Tagen verwenden. Lichtschutz. Wiederholte Gefrier-Tau-Zyklen der rekonstituierten L\u00f6sung vermeiden. Levocarnitin ist hygroskopisch \u2013 Fl\u00e4schchen nach jeder Entnahme umgehend wieder verschlie\u00dfen.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slichkeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sehr gut wasserl\u00f6slich (Zwitterion bei physiologischem pH). Rekonstituiert sich schnell in bakterizidem Wasser oder sterilem Wasser bei leichtem Schwenken. Keine speziellen L\u00f6sungsmittel erforderlich. Arbeitsl\u00f6sungen k\u00f6nnen in Konzentrationen bis zu ~500 mg\/mL ohne Ausf\u00e4llung hergestellt werden.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Was ist L-Carnitin?<\/h2>\n<p><strong>L-Carnitin<\/strong> (Levocarnitin) ist ein kleines, wasserl\u00f6sliches Quaternary-Ammonium-Aminos\u00e4ure-Derivat mit der Summenformel C<sub>7<\/sub>H<sub>15<\/sub>NEIN<sub>3<\/sub> und einer Molek\u00fclmasse von 161,20 g\/mol. Es ist <em>kein Peptid<\/em> \u2014 it is a single-residue zwitterionic molecule derived metabolically from the amino acids L-lysine and L-methionine through a multistep biosynthetic pathway distributed across kidney, liver, and brain. Only the (3R) enantiomer (the L-form \/ levo form \/ levocarnitine) is biologically active; the (3S) enantiomer (D-carnitine) is inactive and is now well-documented to interfere with the L-form&#8217;s transport, which is why pharmaceutical-grade material is supplied as the enantiomerically pure L-form rather than as racemic DL-carnitine. The molecule&#8217;s central physiological function is to serve as the <strong>obligater Tr\u00e4ger<\/strong> f\u00fcr den Transport langkettiger Fetts\u00e4uren (C<sub>12<\/sub>+) across the otherwise-impermeable mitochondrial inner membrane, where they are subsequently broken down by \u03b2-oxidation to acetyl-CoA, the substrate for the citric acid cycle and ATP synthesis. The transport machinery \u2014 carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane, the carnitine\/acylcarnitine translocase (CACT) across the inner membrane, and carnitine palmitoyltransferase II (CPT-II) on the matrix side \u2014 converts free fatty acids into acylcarnitines, ferries them across the bilayer, and releases them again as acyl-CoAs for oxidation. L-Carnitine is therefore the rate-limiting metabolite for fat oxidation in tissues with high oxidative demand: skeletal muscle, cardiac muscle, and liver. L-Carnitine is also a high-affinity buffer of the cellular acyl-CoA \/ free-CoA ratio. By accepting acyl groups onto its hydroxyl side chain, L-carnitine maintains the intracellular pool of free CoA that other CoA-dependent enzymes (pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, fatty-acid \u03b2-oxidation) require to function. Carnitine deficiency therefore produces effects beyond fat oxidation alone \u2014 propagating into pyruvate handling, TCA-cycle flux, and overall mitochondrial bioenergetic balance. L-Carnitine has FDA approval (under the name <em>Levocarnitin<\/em>prim\u00e4ren und sekund\u00e4ren Carnitinmangel <strong>prim\u00e4rer und sekund\u00e4rer Carnitinmangel<\/strong> (oral and IV formulations) and is widely used in contexts that examine mitochondrial bioenergetics, fat oxidation, insulin sensitivity, cardiovascular function, neuroprotection, exercise physiology, and sperm motility. <\/p>\n<h2>Der zentrale Mechanismus von L-Carnitin ist durch mehrere Jahrzehnte mitochondriale Biochemieforschung dokumentiert:<\/h2>\n<p>L-Carnitine&#8217;s central mechanism is documented across several decades of mitochondrial biochemistry studies:<\/p>\n<ul>\n<li><strong>Carnitine palmitoyltransferase I (CPT-I) \u2014 \u00e4u\u00dfere Mitochondrienmembran<\/strong> \u2014 Langkettige Fetts\u00e4uren werden zun\u00e4chst im Zytoplasma zu langkettigen Acyl-CoA aktiviert. CPT-I, das in die \u00e4u\u00dfere Mitochondrienmembran eingebettet ist, \u00fcbertr\u00e4gt die Acylgruppe von CoA auf die Hydroxylgruppe von L-Carnitin, wodurch langkettiges Acylcarnitin entsteht. Dies ist der irreversibel festgelegte und am st\u00e4rksten regulierte Schritt der mitochondrialen Fettoxidation \u2014 CPT-I wird allosterisch durch Malonyl-CoA gehemmt (das Produkt der Acetyl-CoA-Carboxylase im lipogenen Stoffwechsel des Ern\u00e4hrungszustands), was den Mechanismus darstellt, wie Insulin\/Glucagon und das AMPK-System die Fettoxidation gegen\u00fcber der Fettsynthese steuern.<\/li>\n<li><strong>Carnitin\/Acylcarnitin-Translokase (CACT) \u2014 innere Mitochondrienmembran<\/strong> \u2014 Langkettige Acylcarnitine, die durch CPT-I gebildet werden, k\u00f6nnen nicht durch die innere Mitochondrienmembran diffundieren. CACT, ein Antiporter, tauscht im Verh\u00e4ltnis 1:1 zytosolisches Acylcarnitin gegen freies Carnitin in der Matrix aus, wodurch Acylcarnitin in die Matrix gelangt und Carnitin f\u00fcr weitere CPT-I-Zyklen recycelt wird.<\/li>\n<li><strong>Carnitine palmitoyltransferase II (CPT-II) \u2014 innere Mitochondrienmembran, Matrix-seitig<\/strong> \u2014 Im Matrixraum kehrt CPT-II die CPT-I-Reaktion um: Es \u00fcbertr\u00e4gt die Acylgruppe von Carnitin zur\u00fcck auf das Matrix-CoA und regeneriert so langkettiges Acyl-CoA, das nun in die \u03b2-Oxidation eintreten kann. Das freigesetzte freie Carnitin wird \u00fcber CACT zur\u00fcck durch die Membran transportiert, um einen weiteren Transportzyklus zu erm\u00f6glichen.<\/li>\n<li><strong>Pufferung des Acyl-CoA \/ freien-CoA-Verh\u00e4ltnisses und metabolische Flexibilit\u00e4t<\/strong> \u2014 \u00dcber den Langkettentransport hinaus akzeptiert L-Carnitin kurz- und mittelkettige Acylgruppen (Acetylcarnitin, Propionylcarnitin) und fungiert als hochkapazitiver Puffer f\u00fcr das intrazellul\u00e4re Acyl-CoA \/ freie-CoA-Verh\u00e4ltnis. Dies erh\u00e4lt freies CoA f\u00fcr Pyruvatdehydrogenase, \u03b1-Ketoglutaratdehydrogenase und \u03b2-Oxidation. Die Bildung von Acetylcarnitin dient auch als Mechanismus, durch den \u00fcbersch\u00fcssiges Acetyl-CoA \u2013 aus Fasten, Ketogenese oder Bewegung \u2013 sicher gepuffert und durch die mitochondriale Membran exportiert werden kann.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of orally-administered L-carnitine is unusual: oral bioavailability is low (~15%) due to active intestinal saturation, with the remaining 85% subject to extensive bacterial degradation in the colon (yielding TMA and TMAO \u2014 a finding that has attracted attention in cardiovascular studies). Intravenous and intramuscular administration routes achieve much higher plasma levels and bypass the gut-microbial degradation pathway entirely, which is why pharmacological protocols commonly use parenteral administration despite the convenience of oral dosing. <\/p>\n<h2>Published Evidence<\/h2>\n<p>L-Carnitine is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Mitochondriale Funktion und Bioenergetik<\/strong> \u2014 Seahorse-\/Oroboros-Respirometrie, mitochondriales Membranpotential, ATP-Bildungsrate, Fetts\u00e4ureoxidationsrate in prim\u00e4ren Hepatozyten-, Skelettmuskel- und Kardiomyozytenkulturen<\/li>\n<li><strong>Fettoxidation und metabolische Flexibilit\u00e4t<\/strong> \u2014 Wechsel zwischen Glukose- und Fettoxidation in Skelettmuskel und Leber; Modelle zur Umkehr von Insulinresistenz; Studienkohorten mit adip\u00f6sen Nagetieren und DIO<\/li>\n<li><strong>Insulin sensitivity studies<\/strong> \u2014 improvement in skeletal-muscle insulin sensitivity in models of metabolic syndrome and type 2 diabetes preclinical studies; mechanistic dissection of the L-carnitine \/ acyl-CoA buffering \/ pyruvate handling axis<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 angina, heart failure, ischemia-reperfusion injury, cardiomyopathy (in particular doxorubicin-induced cardiotoxicity and primary carnitine-deficiency cardiomyopathy); TMA\/TMAO microbiome-axis cardiovascular studies<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 Alzheimer-disease in-vitro models (acetylcarnitine specifically), Parkinson-disease models, peripheral diabetic neuropathy preclinical models, autism-spectrum studies where carnitine deficiency has been implicated<\/li>\n<li><strong>Sperm motility and male fertility studies<\/strong> \u2014 epididymal acquisition of motility, mitochondrial energetics of sperm flagellar beat, antioxidant protection of spermatozoa; one of the most-studied compounds in male-fertility studies<\/li>\n<li><strong>Exercise physiology and endurance studies<\/strong> \u2014 substrate utilisation during prolonged exercise, glycogen sparing, post-exercise recovery; studies interest in carnitine loading protocols and insulin co-administration to overcome muscle-uptake saturation<\/li>\n<li><strong>Chronic kidney disease \/ haemodialysis studies<\/strong> \u2014 carnitine deficiency is common in dialysis-dependent end-stage renal disease patients and L-carnitine has FDA approval for this indication; preclinical studies continues on dialysis-related cardiomyopathy and muscle weakness<\/li>\n<\/ul>\n<p>For broader context on mitochondrial and metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD\u207a<\/a> (oxidierter Dinucleotid-Coenzym, zentrales Elektronentransport-Substrat), <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (mitochondrial zielgerichtetes kardiolipinbindendes Peptid), und <a href=\"https:\/\/medsbase.com\/de\/mots-c\/\">MOTS-c<\/a> (mitochondrial abgeleitetes metabolisches Regulatorpeptid). Durchsuchen Sie das vollst\u00e4ndige <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">peptides &amp; compounds catalog<\/a> f\u00fcr verwandte Verbindungen. <\/p>\n<h2>Verf\u00fcgbare St\u00e4rken und Konzentrationen<\/h2>\n<p>MedsBase stocks L-Carnitine in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial-St\u00e4rke<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typischer Anwendungsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Packungsgr\u00f6\u00dfen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>600 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 dose-titration protocols, in-vitro mitochondrial-function panels, short-cycle in-vivo work, sperm-motility studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1200 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle or higher-dose protocols \u2014 long-arm metabolic studies, exercise-physiology saturation experiments, multi-cohort work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized levocarnitine zwitterion, \u226599% HPLC purity). Vial doses are deliberately much larger than the peptide range (5\u201320 mg) because L-carnitine is a small molecule used at gram-level doses \u2014 a 600 mg or 1200 mg vial corresponds roughly to a single intravenous dose in rodent or large-animal protocols. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Vergleich \u2014 L-Carnitin vs. NAD\u207a<\/h2>\n<p>L-Carnitin und <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD\u207a<\/a> are the two non-peptide mitochondrial \/ metabolic support compounds in this catalogue, and they target completely different layers of mitochondrial bioenergetics. L-Carnitine sits on the <em>Brennstoffseite<\/em> \u2014 es transportiert langkettige Fetts\u00e4uren in die Matrix zur \u03b2-Oxidation. NAD\u207a wirkt auf der <em>Elektronentransportseite<\/em> \u2014 it is the obligate electron acceptor for \u03b2-oxidation, glycolysis, and the TCA cycle, regenerated by Complex I of the electron transport chain. The two compounds are mechanistically complementary, and protocols sometimes combine them to probe upstream-substrate vs downstream-electron-flux contributions to mitochondrial output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">L-Carnitin<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD\u207a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Chemische Klasse<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Quart\u00e4re Ammonium-Aminos\u00e4ure-Derivat (einzelnes Zwitterion)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dinucleotid-Coenzym (Adenin + Nicotinamidnukleotide, \u00fcber Diphosphat verbunden)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">161.20 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663,43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Rolle in Mitochondrien<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tr\u00e4ger \u2014 Transport langkettiger Fetts\u00e4uren durch die innere Membran<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Elektronenakzeptor f\u00fcr \u03b2-Oxidation, Glykolyse, TCA-Zyklus; Substrat f\u00fcr Sirtuine und PARPs<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fettoxidation, Insulinsensitivit\u00e4t, kardiovaskul\u00e4re Funktion, Spermienmotilit\u00e4t, Sportphysiologie<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sirtuin-Biologie, Langlebigkeit, zellul\u00e4re Alterung, NAD-Achsen-Redox-Regulation<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>FDA-Zulassung<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ja \u2014 Levocarnitin, bei prim\u00e4rem\/sekund\u00e4rem Carnitinmangel (oral und i.v.)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Endogene Biosynthese<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aus L-Lysin und L-Methionin, in Niere\/Leber\/Gehirn<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aus Tryptophan (de novo) oder Nicotinamid\/Niacin (Salvage-Pfad)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Plasmastabilit\u00e4t<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stabil \u2014 Stunden Halbwertszeit<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Instabil \u2014 kurze Minuten Halbwertszeit in L\u00f6sung; oxidiert und zerf\u00e4llt schnell<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typische Dosis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hunderte mg bis Gramm-Bereich (Einzeldosis in Nagetier-\/Gro\u00dftierprotokollen)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Zehner bis Hunderter von mg (Zellkultur: \u00b5M-Konzentrationen)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on long-chain fatty-acid oxidation, cardiovascular metabolic function, insulin sensitivity, or sperm motility, L-Carnitine is the canonical reference compound. For studies focused on sirtuin biology, longevity-axis biochemistry, or NAD-dependent redox regulation, <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD\u207a<\/a> ist das gezieltere Werkzeug. Siehe auch <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin \/ inner-membrane-targeted mitochondrial studies and <a href=\"https:\/\/medsbase.com\/de\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Ben\u00f6tigen Sie BAC-Wasser?<\/strong> Die Rekonstitution jedes lyophilisierten Fl\u00e4schchens erfordert steriles bakteriostatisches Wasser. Kombinieren Sie dieses Produkt mit unserem <a href=\"\/de\/bac-water\/\"><strong>BAC-Wasser (Bakteriostatisches Wasser)<\/strong><\/a> \u2014 30 mL Mehrdosenfl\u00e4schchen, 0,9% Benzylalkohol-konserviert, USP-Qualit\u00e4t.<\/div>\n<h2>Lagerung und Rekonstitution<\/h2>\n<p><strong>Vor der Rekonstitution:<\/strong> Lagern Sie lyophilisierte Fl\u00e4schchen gek\u00fchlt bei 2\u20138 \u00b0C in Originalverpackung als Kurzzeit-Arbeitsvorrat. F\u00fcr Langzeitlagerung frieren Sie unge\u00f6ffnete Fl\u00e4schchen bei \u221220 \u00b0C ein. Lyophilisiertes L-Carnitin ist unter K\u00fchlung bis zu 36 Monate und bei \u221220 \u00b0C bis zu 60 Monate stabil \u2014 deutlich stabiler als die meisten lyophilisierten Peptide, da die Kleinmolek\u00fclstruktur keine Amidbindungen oder Disulfidbr\u00fccken zur Hydrolyse aufweist. Die Verbindung ist jedoch, <strong>hygroskopisch<\/strong>, verschlie\u00dfen Sie Fl\u00e4schchen daher nach jeder Entnahme umgehend und vermeiden Sie l\u00e4ngere Exposition gegen\u00fcber Umgebungsluftfeuchtigkeit. <strong>Rekonstitutionsverfahren:<\/strong> Spritzen Sie das bakterostatische Wasser an der Seitenwand des Fl\u00e4schchens entlang (nicht direkt auf den lyophilisierten Kuchen). Bei einem 600 mg-Fl\u00e4schchen ergeben 3,0 mL bakterostatisches Wasser eine Arbeitskonzentration von 200 mg\/mL; 1,2 mL ergeben eine Stamml\u00f6sung von 500 mg\/mL. Bei einem 1200 mg-Fl\u00e4schchen ergeben 6,0 mL eine Arbeitsstamml\u00f6sung von 200 mg\/mL; 2,4 mL ergeben eine Stamml\u00f6sung von 500 mg\/mL. L-Carnitin l\u00f6st sich durch leichtes Schwenken sehr schnell auf \u2013 typischerweise innerhalb von 10\u201330 Sekunden \u2013 da es ein kleines Zwitterion ohne gefaltete Struktur ist. Nach der Rekonstitution bewahren Sie das Fl\u00e4schchen bei 2\u20138 \u00b0C auf und verwenden es innerhalb von 30 Tagen. Vor Licht sch\u00fctzen. Verwerfen Sie die L\u00f6sung bei Tr\u00fcbung, Partikeln oder Farbver\u00e4nderung. <\/p>\n<h2>H\u00e4ufig gestellte Fragen<\/h2>\n<h3>Ist L-Carnitin ein Peptid?<\/h3>\n<p>Nein. L-Carnitin ist ein kleines Molek\u00fcl, ein quart\u00e4res Ammonium-Aminos\u00e4ure-Derivat (MW 161,20 g\/mol), <em>nicht<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD\u207a<\/a> because it serves a complementary role in mitochondrial \/ metabolic support and is supplied in the same injectable vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Was ist der Unterschied zwischen L-Carnitin und Acetyl-L-Carnitin (ALCAR)?<\/h3>\n<p>Acetyl-L-carnitine is L-carnitine with an acetyl group esterified to the hydroxyl side chain. ALCAR crosses the blood-brain barrier more efficiently and is the form most commonly used in CNS-focused studies (Alzheimer-disease, peripheral neuropathy). The base L-carnitine zwitterion that we supply here is the form used in peripheral metabolic support (cardiovascular, skeletal muscle, sperm motility, dialysis-related deficiency). The two compounds interconvert metabolically through carnitine acetyltransferase. <\/p>\n<h3>Was ist der Unterschied zwischen L-Carnitin und racemischem DL-Carnitin?<\/h3>\n<p>Only the L (3R) enantiomer is biologically active. The D (3S) enantiomer is inactive and is now well-documented to interfere with L-form transport, accumulating in tissue and producing weakness and other adverse effects in long-term high-dose contexts. Pharmaceutical-grade levocarnitine (what we supply) is the enantiomerically pure L-form. The racemic DL-form is obsolete and is no longer used in either clinical or rigorous contexts. <\/p>\n<h3>Why is the dose so much larger than the peptide doses in this catalogue?<\/h3>\n<p>L-Carnitine is a small molecule (MW 161) and is used at gram-level doses \u2014 the body&#8217;s endogenous carnitine pool is approximately 25 g, concentrated in skeletal muscle. Study protocols typically use 100\u2013500 mg\/kg in rodent in-vivo work, which translates to hundreds of milligrams to grams per dose. Compare this to peptides (BPC-157, semaglutide, etc.) where typical doses are 100 \u00b5g to 5 mg per administration \u2014 three to four orders of magnitude smaller, reflecting the different molecular weights and the different receptor \/ mechanism scales. <\/p>\n<h3>What is the TMA \/ TMAO question I see in cardiovascular studies?<\/h3>\n<p>A subset of L-carnitine ingested orally is degraded by gut bacteria to trimethylamine (TMA), which the liver then oxidises to trimethylamine-N-oxide (TMAO). Elevated TMAO levels have been associated in epidemiological studies with adverse cardiovascular events, raising a controversy about whether long-term high-dose oral L-carnitine supplementation may be net-beneficial or net-harmful for cardiovascular endpoints. The question is active and unresolved. Parenteral L-carnitine bypasses the gut-microbial degradation pathway and is not subject to this concern. <\/p>\n<h3>What does CPT-I inhibition mean in metabolic support?<\/h3>\n<p>Carnitine palmitoyltransferase I (CPT-I) is the rate-limiting enzyme for mitochondrial long-chain fatty-acid uptake. Etomoxir is a classical CPT-I inhibitor used to block fat oxidation in study models; it is the pharmacological tool counterpart to the L-carnitine substrate. Study protocols sometimes combine L-carnitine supplementation (substrate side) with CPT-I inhibition (enzymatic side) to dissect substrate-limited vs enzyme-limited fat oxidation in different tissues and conditions. <\/p>\n<h3>Can I combine L-Carnitine with NAD\u207a in the same protocol?<\/h3>\n<p>Yes \u2014 the two compounds target different layers of mitochondrial bioenergetics (substrate transport vs electron transport), and combination is commonly used in studies that aims to probe upstream vs downstream limitations on mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. <\/p>\n<h3>What route of administration is used in published studies?<\/h3>\n<p>Intravenous and intramuscular routes are most common in pharmacological studies because they bypass the low (~15%) oral bioavailability and the gut-microbial TMA\/TMAO degradation pathway. Subcutaneous administration is used in some rodent protocols. Oral administration is used in pharmacokinetic and nutritional studies where the bioavailability question is itself the studies focus. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Mitochondrialer Langketten-Fetts\u00e4ure-Shuttle (kein Peptid)<br \/>\n\u2705 CPT-I-\/CACT-\/CPT-II-Transportmaschinerie-Substrat<br \/>\n\u2705 Erforscht in Fettoxidations-, Insulinsensitivit\u00e4ts- und kardiovaskul\u00e4ren Modellen<br \/>\n\u2705 Acyl-CoA \/ free-CoA ratio buffer; sperm-motility studies<br \/>\n\u2705 Levocarnitin FDA-zugelassen bei Carnitinmangel (oral und i.v.)<\/p>\n<p><strong>L-Carnitin<\/strong> enth\u00e4lt synthetisches Levocarnitin.<\/p>","protected":false},"featured_media":71414,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6472,6469,6470,6471],"class_list":["post-71409","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-amino-acid-derivative","product_tag-l-carnitine","product_tag-levocarnitine","product_tag-mitochondrial","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/comments?post=71409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media\/71414"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media?parent=71409"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_brand?post=71409"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_cat?post=71409"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_tag?post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}